We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Oscar shares have soared 75% since raising revenue guidance
But analysts reversed course on their profit forecasts and now project losses
Average price targets remain near $12, with Wells Fargo recently raising to $14
Oscar Health ((OSCR - Free Report) ) is a $5 billion digital health-insurance company that was expected to see a strong rise to profitability this year into 2026.
But even after raising top line guidance this year to $12-12.2 billion from $11.2-11.3 billion, analysts reversed course on their EPS forecast by moving the consensus from $0.61 to a loss of $1.42 in the past few months.
Next year's profit projection also flipped from $0.54 to a loss of $0.67. It's also worth noting that analysts haven't moved next year's revenue consensus from $11.26B, which would represent a 6.6% drop vs. this year's new guide.
Digital Innovator in a Competitive Space
Oscar Health’s primary competitors in the health insurance sector include both technology-driven upstarts and large legacy providers. Major direct competitors are Clover Health, Bright Health, Lemonade, NeueHealth, and Sidecar Health—all of which focus on digital-first, member-centric insurance or care delivery models.
Additionally, Oscar competes against traditional insurers such as UnitedHealthcare, Blue Cross Blue Shield, and CNO Financial. The competitive landscape ranges from specialized insurtech firms to established payors with scale, network breadth, and brand recognition.
Since Oscar Health’s 2025 guidance update, shares have rallied strongly from $13 to $23 as if a floor was put in with the upward revenue guide but downward profit outlook.
And analyst price targets have shifted upward begrudgingly, with the average target near $11, representing over 50% downside. Consistent with this pattern, yesterday Wells Fargo raised its target from $10 to $14 but reaffirmed its Underweight rating.
Bottom line: Investor optimism seems to be ahead of the fundamentals for OSCR. Waiting until the next quarterly report for better visibility is probably the best move as analysts will have more data to re-work their models. The Zacks Rank will let you know.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bear of the Day: Oscar Health (OSCR)
Key Takeaways
Oscar Health ((OSCR - Free Report) ) is a $5 billion digital health-insurance company that was expected to see a strong rise to profitability this year into 2026.
But even after raising top line guidance this year to $12-12.2 billion from $11.2-11.3 billion, analysts reversed course on their EPS forecast by moving the consensus from $0.61 to a loss of $1.42 in the past few months.
Next year's profit projection also flipped from $0.54 to a loss of $0.67. It's also worth noting that analysts haven't moved next year's revenue consensus from $11.26B, which would represent a 6.6% drop vs. this year's new guide.
Digital Innovator in a Competitive Space
Oscar Health’s primary competitors in the health insurance sector include both technology-driven upstarts and large legacy providers. Major direct competitors are Clover Health, Bright Health, Lemonade, NeueHealth, and Sidecar Health—all of which focus on digital-first, member-centric insurance or care delivery models.
Additionally, Oscar competes against traditional insurers such as UnitedHealthcare, Blue Cross Blue Shield, and CNO Financial. The competitive landscape ranges from specialized insurtech firms to established payors with scale, network breadth, and brand recognition.
Since Oscar Health’s 2025 guidance update, shares have rallied strongly from $13 to $23 as if a floor was put in with the upward revenue guide but downward profit outlook.
And analyst price targets have shifted upward begrudgingly, with the average target near $11, representing over 50% downside. Consistent with this pattern, yesterday Wells Fargo raised its target from $10 to $14 but reaffirmed its Underweight rating.
Bottom line: Investor optimism seems to be ahead of the fundamentals for OSCR. Waiting until the next quarterly report for better visibility is probably the best move as analysts will have more data to re-work their models. The Zacks Rank will let you know.